Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest YM BioSciences Inc. Stories

2011-06-03 14:00:00

- Favorable safety and durable efficacy responses recorded - - Early Dose Expansion data consistent with initial findings - - YM provides update on development plans for CYT387 - MISSISSAUGA, ON, June 3, 2011 /PRNewswire/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), today reported updated interim safety and efficacy results from the Phase I/II study of its JAK1/JAK2 inhibitor, CYT387, for the treatment of myelofibrosis. The results are being presented today in a poster...

2011-05-31 06:00:00

MISSISSAUGA, ON, May 31, 2011 /PRNewswire/ - YM BioSciences Inc. (NYSE Amex: YMI), (TSX: YM), today announced that it has received positive opinions from the Committee for Orphan Medicinal Products of the European Commission to grant Orphan Medicinal Product Designation to its JAK1/JAK2 inhibitor, CYT387, for the treatment of primary myelofibrosis, post-polycythaemia vera myelofibrosis and post-essential thrombocythaemia myelofibrosis.  Myelofibrosis is a chronic debilitating unmet...

2011-05-30 16:00:00

- Eleven abstracts on nimotuzumab to be presented at ASCO - - Manufacturing scale-up completed - - YM to close North American trials and transition patients to Special Access Program - MISSISSAUGA, ON, May 30, 2011 /PRNewswire/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), today provided an update on the development program for nimotuzumab, including its North American clinical program for nimotuzumab, manufacturing scale-up activities, and data presentations anticipated for...

2011-05-18 17:05:00

- Poster with broader update of trial results to be presented at ASCO - MISSISSAUGA, ON, May 18 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI) (TSX: YM), today reported updated interim results for the first 60 patients with high/intermediate-risk myelofibrosis who have completed a minimum of three cycles of treatment (12 weeks) in its ongoing Phase I/II multi-center study. "In addition to reducing spleen volumes and improving constitutional symptoms, CYT387 continues...

2011-05-11 16:57:00

MISSISSAUGA, ON, May 11 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), a life sciences company developing a diverse portfolio of promising hematology and cancer-related products, today reported operational and financial results for the third quarter of fiscal 2011, ended March 31, 2011. "We continue to advance our JAK1/JAK2 inhibitor CYT387 in the clinic and look forward to reporting interim data from our Phase I/II trial at ASCO in June, with mature data...

2011-04-18 13:49:00

MISSISSAUGA, ON, April 18 /PRNewswire/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), today announced that updated interim anemia response data were reported for the first 60 patients enrolled in the Phase I/II trial of its JAK1/JAK2 inhibitor, CYT387, for the treatment of myelofibrosis. The results were disclosed by Dr. Ayalew Tefferi (Mayo Clinic, Rochester, Minnesota), Chair of the Study, during the First Annual Florence Meeting on Myeloproliferative Neoplasms held in Florence,...

2011-03-18 00:00:26

Why YM BioSciences Inc. will continue its uptrend? (Vocus/PRWEB) March 16, 2011 TooNiceStocks research has unveiled YM Biosciences Inc. has been the focus of attention from retail to institutional investors. TooNiceStocks found Institutional holdings currently accounts for 43% of the approximately 110 million outstanding shares. This shows the confidence in the company's pipeline specifically CYT387, for the treatment of Myelofibrosis. Myelofibrosis is a proliferation of an abnormal type of...

2011-02-10 07:00:00

MISSISSAUGA, ON, Feb. 10 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), a life sciences product development company advancing a diverse portfolio of promising hematology and cancer-related products at various stages of development, today reported operational and financial results for the second quarter of fiscal 2011, ended December 31, 2010. "At the American Society of Hematology Annual Meeting in December 2010, we presented interim data from the Phase I/II trial of...

2011-01-20 16:00:00

MISSISSAUGA, ON, Jan. 20 /PRNewswire/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), a life sciences product development company advancing a diverse portfolio of promising hematology and cancer-related products at various stages of development, today announced that results were reported from a randomized Phase II gastric cancer study of nimotuzumab being conducted by its licensees, Daiichi Sankyo Co., Ltd. in Japan and Kuhnil Pharma Co. Ltd., in Korea. "The overall findings of the study are...

2010-12-23 15:40:00

MISSISSAUGA, ON, Dec. 23 /PRNewswire/ - YM BioSciences Inc. (NYSE Amex: YMI; TSX: YM) announced today that, in connection with its previously announced public offering for total net proceeds before expenses of US $37,650,000, the underwriters have exercised in full their Over-Allotment Option to purchase an additional 3,750,000 common shares of YM at US $1.60 per share for additional net proceeds of US $5,665,000. The underwriters are Roth Capital Partners, LLC, which acted as the...